Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12345678910111213...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lactylation-Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib. (Pubmed Central) -  Feb 20, 2025   
    The NPs achieved tumor-targeting, controlled-release, and biocompatibility, making them a promising therapeutic strategy for mitigating lenvatinib resistance. This study identifies HECTD2 as a nanotherapeutic target for overcoming lenvatinib resistance, providing a theoretical basis and translational application for HCC treatment.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immunotherapy for endometrial cancer. (Pubmed Central) -  Feb 20, 2025   
    The incidence of irAEs is higher for combination therapy with CT or lenvatinib compared with ICI therapy alone. Even though they are rarely fatal, irAEs should be addressed promptly.
  • ||||||||||  Lysodren (mitotane) / Perrigo Company, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Review, Journal:  Oncological Management of Adrenocortical Carcinoma: An Update and Critical Review. (Pubmed Central) -  Feb 18, 2025   
    The EIF4A3/circFADS1/GSK3?/?-catenin axis is discovered to hold promise as a novel therapeutic target for hepatocellular carcinoma, while circFADS1 is also a significant factor in lenvatinib resistance. Those with recurrent or metastatic cancers can be considered for the combination of etoposide, doxorubicin, cisplatin and mitotane (EDP-M) on the basis of results of a single randomised trial...Cabozantinib or lenvatinib alone or in combination, show the greatest promise with disease control rates of 50% or greater, and progression-free survival in excess of 6
  • ||||||||||  Retrospective data, Journal:  Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis. (Pubmed Central) -  Feb 18, 2025   
    Those with recurrent or metastatic cancers can be considered for the combination of etoposide, doxorubicin, cisplatin and mitotane (EDP-M) on the basis of results of a single randomised trial...Cabozantinib or lenvatinib alone or in combination, show the greatest promise with disease control rates of 50% or greater, and progression-free survival in excess of 6 The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes, and the new drug apatinib demonstrates promise for potentially superior performance.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer (clinicaltrials.gov) -  Feb 18, 2025   
    P2,  N=30, Active, not recruiting, 
    CaboNivoIpi had low ORRs and a high rate of grade ?3 treatment-related AEs. Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Targeting CDK2 Confers Vulnerability to Lenvatinib Via Driving Senescence in Anaplastic Thyroid Cancer. (Pubmed Central) -  Feb 17, 2025   
    Combination of CDK2 inhibitors in clinical trials (Dinaciclib or PF-07104091) and lenvatinib markedly suppressed growth of xenograft tumors from the lenvatinib-resistant patient. The findings support the combination therapy strategy of lenvatinib and CDK2 inhibitor for lenvatinib-resistant ATC patients with high CDK2 expression.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Nuclear KRT19 is a transcriptional co-repressor promoting histone deacetylation and liver tumorigenesis. (Pubmed Central) -  Feb 17, 2025   
    Our data show that nuclear KRT19 acts as a transcriptional corepressor through promoting the deacetylase activity of the CoREST complex, resulting in dedifferentiation of liver cancer. These findings reveal a previously unrecognized function of KRT19 in directly shaping the epigenetic landscape in cancer.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma. (Pubmed Central) -  Feb 17, 2025   
    These combination therapies have also exhibited superior response rates and disease control, with manageable and often less severe adverse events relative to systemic treatments. This article is based on the review by Zhou et al and aims to discuss the current status and future directions in the treatment of HCC, emphasizing the role of HAIC and its integration with novel therapeutic agents.
  • ||||||||||  carboplatin / Generic mfg., pemetrexed / Generic mfg.
    Journal, Metastases:  Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers. (Pubmed Central) -  Feb 12, 2025   
    Trial completion date: Dec 2028 --> Dec 2027 This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  LITESPARK-016: Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) (clinicaltrials.gov) -  Feb 12, 2025   
    P2,  N=730, Active, not recruiting, 
    This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers. Recruiting --> Active, not recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Circulating T (Pubmed Central) -  Feb 11, 2025   
    Recruiting --> Active, not recruiting analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Clinical data, Journal:  Contrasting cytotoxic and regulatory T (Pubmed Central) -  Feb 11, 2025   
    analyze hepatocellular carcinoma patients treated with anti-PD-1 and lenvatinib, identifying a circulating CD8+ T Notably, an underexplored KIR+ CD8+ T
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), sorafenib / Generic mfg.
    Journal:  The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) -  Feb 11, 2025   
    Cox multivariate analyses identified combination D-TACE-HAIC + lenvatinib+ PD-1 inhibitor treatment as being independently associated with patient PFS and OS. In summary, D-TACE-HAIC + lenvatinib + PD-1 inhibitor treatment exhibits a favorable safety profile, outperforming TACE + sorafenib treatment for unresectable HCC patients while improving overall rates of translational efficacy, increasing rates of surgical conversion, prolonging patient survival, and conferring long-term survival benefits.
  • ||||||||||  Retrospective data, Journal:  Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? (Pubmed Central) -  Feb 7, 2025   
    This suggests that circCCNY could serve as a promising therapeutic target in HCC treatment and a potential biomarker for predicting HCC sensitivity to lenvatinib. S-TKIs permitted to tailor systemic treatment based on disease location, tumour volume and patient comorbidities, achieving satisfactory tolerance and outcome in selected patients with an actionable driver mutation and with contraindications to angiogenesis inhibitors or candidates for redifferentiation therapy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date:  HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma (clinicaltrials.gov) -  Feb 6, 2025   
    P=N/A,  N=300, Recruiting, 
    In conclusion, our case demonstrates that palbociclib plus lenvatinib is a promising chemotherapy-free second-line treatment for intrahepatic cholangiocarcinoma with a CDKN2A/2B deletion. Trial completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
    Journal:  Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment. (Pubmed Central) -  Feb 6, 2025   
    Gene-chemical interaction network studies uncovered that existing drug molecules, including sorafenib, regorafenib, cabozantinib, and lenvatinib, can be used as leads to identify novel drugs, and the identified hub genes can be promising drug targets. The current study underscores the significance of targeting these hub genes and utilizing existing molecules to generate new molecules to combat liver cancer effectively and can be further explored in terms of drug discovery research to develop treatments for HCC.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Clinical, Observational data, Retrospective data, Review, Journal:  Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway. (Pubmed Central) -  Feb 5, 2025   
    Collectively, these findings demonstrated that lenvatinib inhibits CCA progression by targeting the FGF19/PI3K/AKT signaling pathway. The present study provides novel experimental evidence for the potential clinical application of lenvatinib in CCA, which also highlights the promising role of targeting FGF19 in combined therapeutic approaches for CCA.
  • ||||||||||  Journal:  Multiple Subcutaneous Metastases in Endometrial Cancer Treated With Systemic Chemotherapy: A Case Report and Review of the Literature. (Pubmed Central) -  Feb 5, 2025   
    She was then transitioned to a regimen of lenvatinib and pembrolizumab...The patient is currently receiving pembrolizumab as maintenance therapy and has remained recurrence-free for 18 months. While no standardized therapeutic protocol exists for the management of subcutaneous metastasis in EC due to its extremely low incidence, this report provides evidence for the potential efficacy of chemotherapy combined with targeted immunotherapy in the treatment of unresectable subcutaneous metastases in EC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov) -  Feb 3, 2025   
    P2,  N=30, Recruiting, 
    Treatment-na Trial primary completion date: Dec 2024 --> Jul 2025
  • ||||||||||  Biomarker, Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. (Pubmed Central) -  Jan 31, 2025   
    Additionally, biomarkers have been developed for endometrial cancer, enabling gynecologists to pursue treatment options based on the biomarkers detected for better treatment outcomes. In this article, we review the clinical trials of immune checkpoint inhibitors for advanced or recurrent endometrial cancer.
  • ||||||||||  Xalkori (crizotinib) / Pfizer
    Journal, PD(L)-1 Biomarker:  Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib. (Pubmed Central) -  Jan 31, 2025   
    In this article, we review the clinical trials of immune checkpoint inhibitors for advanced or recurrent endometrial cancer. Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Exelixis
    Journal, Metastases:  A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma. (Pubmed Central) -  Jan 31, 2025   
    A 71-year-old man presented to our hospital for treatment of HCC with chronic hepatitis C. He was refractory to sorafenib, lenvatinib, regorafenib, and ramucirumab and started atezolizumab and bevacizumab therapy in November 2020...The patient did not show disease progression for 11 months without receiving any treatment for HCC. To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy:  Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients (clinicaltrials.gov) -  Jan 31, 2025   
    P2,  N=30, Active, not recruiting, 
    To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC. Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026